- Home
- PETS vs EYEN Comparison
PETS vs EYEN Comparison
Compare PETS & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- EYEN
- Stock Information
- Founded
- PETS 1996
- EYEN 2014
- Country
- PETS United States
- EYEN United States
- Employees
- PETS N/A
- EYEN N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- EYEN Health Care
- Exchange
- PETS Nasdaq
- EYEN Nasdaq
- Market Cap
- PETS 82.0M
- EYEN 38.2M
- IPO Year
- PETS N/A
- EYEN 2018
- Fundamental
- Price
- PETS $4.07
- EYEN $0.55
- Analyst Decision
- PETS Sell
- EYEN Strong Buy
- Analyst Count
- PETS 2
- EYEN 2
- Target Price
- PETS $3.50
- EYEN $12.00
- AVG Volume (30 Days)
- PETS 182.6K
- EYEN 879.0K
- Earning Date
- PETS 11-06-2024
- EYEN 11-11-2024
- Dividend Yield
- PETS 29.41%
- EYEN N/A
- EPS Growth
- PETS N/A
- EYEN N/A
- EPS
- PETS N/A
- EYEN N/A
- Revenue
- PETS $270,772,000.00
- EYEN $31,405.00
- Revenue This Year
- PETS N/A
- EYEN $50,309.30
- Revenue Next Year
- PETS $3.27
- EYEN $421.63
- P/E Ratio
- PETS N/A
- EYEN N/A
- Revenue Growth
- PETS 2.26
- EYEN N/A
- 52 Week Low
- PETS $2.90
- EYEN $0.37
- 52 Week High
- PETS $8.27
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- PETS 56.76
- EYEN 52.60
- Support Level
- PETS $3.78
- EYEN $0.52
- Resistance Level
- PETS $4.17
- EYEN $0.59
- Average True Range (ATR)
- PETS 0.18
- EYEN 0.05
- MACD
- PETS -0.01
- EYEN 0.01
- Stochastic Oscillator
- PETS 62.22
- EYEN 66.45
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.